Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

731

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Metastatic Cancer
Malignant Neoplastic Disease

Interventions

DRUG: MRTX849
DRUG: Pembrolizumab
DRUG: Cetuximab
DRUG: Afatinib

Sponsor

Mirati Therapeutics Inc.